Related references
Note: Only part of the references are listed.Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Somedeb Ball et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials.
Richard R. Furman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Non-Aspergillusinvasive mould infections in patients treated with ibrutinib
Amalia Anastasopoulou et al.
MYCOSES (2020)
Infections Related to Biologics: Agents Targeting B Cells
Maria J. Leandro
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies
Andrew Kin et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)
Lower Mortality Associated With Adjuvant Corticosteroid Therapy in Non-HIV-Infected Patients With Pneumocystis jirovecii Pneumonia: A Single-Institution Retrospective US Cohort Study
William Mundo et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Infectious complications in patients treated with immune checkpoint inhibitors
Jean-Denis Karam et al.
EUROPEAN JOURNAL OF CANCER (2020)
A review of cancer immunotherapy: from the past, to the present, to the future
K. Esfahani et al.
CURRENT ONCOLOGY (2020)
Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors
Christine E. Ryan et al.
BLOOD ADVANCES (2020)
Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia
Matthew Stankowicz et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
Antonio Cuneo et al.
HEMATOLOGICAL ONCOLOGY (2019)
Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib
Kaelyn C. Cummins et al.
LEUKEMIA & LYMPHOMA (2019)
Reporting infections in clinical trials of patients with haematological malignancies
N. Tau et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study
Rosa Ruchlemer et al.
MYCOSES (2019)
Azole antifungals and new targeted therapies for hematological malignancy
Julian Lindsay et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2019)
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia
Benjamin W. Teh et al.
LEUKEMIA & LYMPHOMA (2019)
Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis
Jian Yu et al.
HEMATOLOGY (2019)
Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
Marissa A. Zarakas et al.
CURRENT FUNGAL INFECTION REPORTS (2019)
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents
Ibrahim Aldoss et al.
BLOOD ADVANCES (2019)
Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections
Katie Bechman et al.
CURRENT FUNGAL INFECTION REPORTS (2019)
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Steven Coutre et al.
BLOOD (2018)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
David Ghez et al.
BLOOD (2018)
Risk of hepatitis B virus reactivation in patients treated with ibrutinib
Sarah P. Hammond et al.
BLOOD (2018)
Ibrutinib blocks Btk-dependent NF-κB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis
Amelia Bercusson et al.
BLOOD (2018)
Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies
Benjamin W. Teh et al.
BLOOD REVIEWS (2018)
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Matthew S. Davids et al.
CLINICAL CANCER RESEARCH (2018)
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Tilly Varughese et al.
CLINICAL INFECTIOUS DISEASES (2018)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
J. Aguilar-Company et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
L. Drgona et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
M. Reinwald et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)
M. Mikulska et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies
Benjamin F. Tillman et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer
Lorena Ostios-Garcia et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy
David Hsiehchen et al.
ONCOLOGY (2018)
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies
Caspar da Cunha-Bang et al.
DRUGS (2018)
Ruxolitinib-associated infections: A systematic review and meta-analysis
Federico Lussana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Invasive Mold Infections in Patients with Chronic Lymphoproliferative Disorders
Davide Facchinelli et al.
CURRENT FUNGAL INFECTION REPORTS (2018)
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways
Georgios Chamilos et al.
CLINICAL INFECTIOUS DISEASES (2018)
Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib
Julia A. Messina et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab
Anne C. Wilke et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Ibrutinib may impair serological responses to influenza vaccination
Abby P. Douglas et al.
HAEMATOLOGICA (2017)
Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect
G. Moulis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
Yingtian Wang et al.
ONCOTARGET (2017)
Ibrutinib may impair serological responses to influenza vaccination
Abby P. Douglas et al.
HAEMATOLOGICA (2017)
Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis
Xi Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy
Jason N. Barreto et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer
Christine A. Garcia et al.
CANCER INVESTIGATION (2016)
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
Maria Del Castillo et al.
CLINICAL INFECTIOUS DISEASES (2016)
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients
Johan Maertens et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Prevention and Treatment of Cancer-Related Infections, Version 2.2016
Lindsey Robert Baden et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Kohei Fujita et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials
Laurie H. Sehn et al.
BLOOD (2016)
Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
Ohad Benjamini et al.
BLOOD (2016)
Targeting Immune Checkpoints in Hematologic Malignancies
Gheath Alatrash et al.
PHARMACOLOGICAL REVIEWS (2016)
Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia
Song-Yau Wang et al.
ANNALS OF HEMATOLOGY (2015)
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials
Saeed Rafii et al.
CLINICAL CANCER RESEARCH (2015)
Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials
Wei-Xiang Qi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis
Qingling Hua et al.
JOURNAL OF CHEMOTHERAPY (2015)
Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab
Ugur Uslu et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R. Zeiser et al.
LEUKEMIA (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis
Xuqin Jiang et al.
PLOS ONE (2015)
Regulation of T cells by mTOR: the known knowns and the known unknowns
Kristen N. Pollizzi et al.
TRENDS IN IMMUNOLOGY (2015)
Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis
Wei-Xiang Qi et al.
BMC MEDICINE (2014)
Progressive Multifocal Leukoencephalopathy Associated With Brentuximab Vedotin Therapy A Report of 5 Cases from the Southern Network on Adverse Reactions (SONAR) Project
Kenneth R. Carson et al.
CANCER (2014)
Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis
Tomohiro Funakoshi et al.
CANCER TREATMENT REVIEWS (2014)
Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors
Melodie Carbonnaux et al.
INVESTIGATIONAL NEW DRUGS (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Treatment-Related Mortality With Everolimus in Cancer Patients
Robert Wesolowski et al.
ONCOLOGIST (2014)
Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2013)
A Case of Pneumocystis Pneumonia Associated with Everolimus Therapy for Renal Cell Carcinoma
Yoshinobu Saito et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis
Wei-Xiang Qi et al.
PLOS ONE (2013)
Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier
Shinta Mizuno et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2013)
Hepatitis B reactivation related to everolimus
Sema Sezgin Goksu et al.
WORLD JOURNAL OF HEPATOLOGY (2013)
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
L. Albiges et al.
ANNALS OF ONCOLOGY (2012)
Brentuximab associated progressive multifocal leukoencephalopathy
Pankaj Jalan et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hepatitis B Virus Reactivation in Chronic Myeloid Leukemia Treated with Various Tyrosine Kinase Inhibitors: Multicenter, Retrospective Study
Sung-Hyun Kim et al.
BLOOD (2012)
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
A. M. Evens et al.
ANNALS OF ONCOLOGY (2011)
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
Simone Lanini et al.
BMC MEDICINE (2011)
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
Hugues de Lavallade et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone
Sarah Kamel et al.
LEUKEMIA & LYMPHOMA (2010)
Rituximab-Associated Neutropenia
Kieron Dunleavy et al.
SEMINARS IN HEMATOLOGY (2010)
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis
Sercan Aksoy et al.
LEUKEMIA & LYMPHOMA (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-hodgkin's lymphoma
Christos Emmanouilides et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Infectious complications of monoclonal antibodies used in cancer therapy - A systematic review of the evidence from randomized controlled trials
Petros I. Rafailidis et al.
CANCER (2007)
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders
Stanley I. Martin et al.
CLINICAL INFECTIOUS DISEASES (2006)
Immune defects in patients with chronic lymphocytic leukemia
F Ravandi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab
KA Thursky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Share Paper
